Sintilimab Combined With Bevacizumab Biosimilar for Potentially Resectable Intermediate HCC
Status:
Not yet recruiting
Trial end date:
2023-05-01
Target enrollment:
Participant gender:
Summary
This is a Phase Ib study to evaluate the safety and efficacy of sintilimab combined with
bevacizumab biosimilar in patients with potentially resectable intermediate hepatocellular
carcinoma (HCC).